Solid Biosciences Inc.
SLDBFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Solid Biosciences Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Solid Biosciences Inc. — 10-K filed Mar 23, 2023
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 11, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Farther Finance Advisors, LLC | 2026-03-31 | 1,220 | $9K | SEC filing |
| Parallel Advisors, LLC | 2026-03-31 | 125 | $900 | SEC filing |
| Fortitude Family Office, LLC | 2026-03-31 | 77 | $554 | SEC filing |
| Sound Income Strategies, LLC | 2026-03-31 | 1,005 | $7.42K | SEC filing |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 517 | $3.72K | SEC filing |
| ROTHSCHILD INVESTMENT LLC | 2026-03-31 | 75 | $540 | SEC filing |
| TWIN PEAKS WEALTH ADVISORS, LLC | 2026-03-31 | 5 | $36 | SEC filing |
| Essential Partners LLC | 2026-03-31 | 3,030 | $21.8K | SEC filing |
| ROTHSCHILD INVESTMENT LLC | 2025-12-31 | 75 | $423 | SEC filing |
| Parallel Advisors, LLC | 2025-12-31 | 125 | $705 | SEC filing |
| EverSource Wealth Advisors, LLC | 2025-12-31 | 533 | $3.01K | SEC filing |
| Farther Finance Advisors, LLC | 2025-12-31 | 374 | $2.11K | SEC filing |
| Essential Partners LLC | 2025-12-31 | 263 | $1.48K | SEC filing |
| Parallel Advisors, LLC | 2025-09-30 | 125 | Not shown | SEC filing |
| EverSource Wealth Advisors, LLC | 2025-09-30 | 533 | Not shown | SEC filing |
| ROTHSCHILD INVESTMENT LLC | 2025-09-30 | 75 | Not shown | SEC filing |
| Farther Finance Advisors, LLC | 2025-09-30 | 11,497 | Not shown | SEC filing |
| Essential Partners LLC | 2025-09-30 | 263 | Not shown | SEC filing |
| Essential Partners LLC | 2025-06-30 | 263 | Not shown | SEC filing |
| Parallel Advisors, LLC | 2025-06-30 | 125 | Not shown | SEC filing |
- Each value is checked against Solid Biosciences Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 7 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Essential Partners LLC: 263 shares reported 2025-12-31; 3,030 shares reported 2026-03-31.
- ROTHSCHILD INVESTMENT LLC: 75 shares reported 2025-12-31; 75 shares reported 2026-03-31.
- EverSource Wealth Advisors, LLC: 533 shares reported 2025-12-31; 517 shares reported 2026-03-31.
- Parallel Advisors, LLC: 125 shares reported 2025-12-31; 125 shares reported 2026-03-31.
- Farther Finance Advisors, LLC: 374 shares reported 2025-12-31; 1,220 shares reported 2026-03-31.
- Essential Partners LLC: 263 shares reported 2025-09-30; 263 shares reported 2025-12-31.
- ROTHSCHILD INVESTMENT LLC: 75 shares reported 2025-09-30; 75 shares reported 2025-12-31.
- EverSource Wealth Advisors, LLC: 533 shares reported 2025-09-30; 533 shares reported 2025-12-31.
- Parallel Advisors, LLC: 125 shares reported 2025-09-30; 125 shares reported 2025-12-31.
- Farther Finance Advisors, LLC: 11,497 shares reported 2025-09-30; 374 shares reported 2025-12-31.
- Essential Partners LLC: 263 shares reported 2025-06-30; 263 shares reported 2025-09-30.
- ROTHSCHILD INVESTMENT LLC: 75 shares reported 2025-06-30; 75 shares reported 2025-09-30.
Showing the 12 most recent filer reports.
4 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Solid Biosciences Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-04 · Cumbo Alexander: Larger than 43 of the 44 other insider sales of Common Stock on file. SEC filing
- 2026-02-02 · Tan Kevin: Larger than 40 of the 44 other insider sales of Common Stock on file. SEC filing
- 2026-02-02 · Cumbo Alexander: Larger than all 44 other insider sales of Common Stock on file. SEC filing
- 2026-02-02 · Howton David T: Larger than 42 of the 44 other insider sales of Common Stock on file. SEC filing
- 2026-02-02 · Brooks Gabriel: Larger than 41 of the 44 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-18 | Hanrahan Jessie · Chief Regulatory Officer | Common Stock | S — Open market or private sale | −4,134 | 5.82 | SEC filing |
| 2026-02-18 | Herzich Paul · Chief Technology Officer | Common Stock | S — Open market or private sale | −3,616 | 5.82 | SEC filing |
| 2026-02-18 | Tan Kevin · CFO & Treasurer | Common Stock | S — Open market or private sale | −5,404 | 5.82 | SEC filing |
| 2026-02-18 | Cumbo Alexander · President and CEO | Common Stock | S — Open market or private sale | −16,644 | 5.82 | SEC filing |
| 2026-02-18 | Ganot Ilan · Director | Common Stock | S — Open market or private sale | −2,658 | 5.82 | SEC filing |
| 2026-02-18 | Brooks Gabriel · Chief Medical Officer | Common Stock | S — Open market or private sale | −0 | 5.82 | SEC filing |
| 2026-02-18 | Howton David T · Chief Operating Officer | Common Stock | S — Open market or private sale | −7,469 | 5.82 | SEC filing |
| 2026-02-04 | Howton David T · Chief Operating Officer | Common Stock | S — Open market or private sale | −18,894 | 6.44 | SEC filing |
Showing 8 of 17 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-10 | SMITH IAN F · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Kahn Clare · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Keresty Georgia · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Freed Martin I · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Nagendran Sukumar · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Stone Adam Leo · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Sullivan Lynne Marie · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
| 2026-06-10 | Ganot Ilan · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +77,500 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.